Niagen Bioscience
NAGE
75 hedge funds and large institutions have $25.3M invested in Niagen Bioscience in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 25 reducing their positions, and 19 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7.52% less ownership
Funds ownership: 29.72% → 22.2% (-7.5%)
9% less funds holding
Funds holding: 82 → 75 (-7)
15% less call options, than puts
Call options by funds: $100K | Put options by funds: $117K
16% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 25
21% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 19
49% less capital invested
Capital invested by funds: $49.9M → $25.3M (-$24.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tieton Capital Management
Yakima,
Washington
|
+$1.67M |
| 2 |
Millennium Management
New York
|
+$1.49M |
| 3 |
Renaissance Technologies
New York
|
+$625K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$517K |
| 5 |
E
Ergoteles
New York
|
+$450K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.23M |
| 2 |
YRHAM
Yong Rong (HK) Asset Management
Sheung Wan,
Hong Kong
|
-$2.67M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.88M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1.48M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.36M |
NAGE Hedge Fund Activity: Q2 2022 in Review
75 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q2 2022, worth a combined $25.3M — down 49% from $49.9M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of NAGE and 15 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 21 added.
The largest buyer was Tieton Capital Management, adding an estimated $1.67M. The largest seller was BlackRock, cutting an estimated $4.23M.
- 75 institutional investors held Niagen Bioscience (NAGE) as of Q2 2022, down from 82 in Q1 2022.
- Funds reported $25.3M of Niagen Bioscience stock for Q2 2022, down 49% quarter-over-quarter.
- 15 funds opened new Niagen Bioscience positions in Q2 2022 and 19 closed out, a net change of -4 holders.
- The largest Niagen Bioscience buyer in Q2 2022 was Tieton Capital Management, an estimated $1.67M added.
- The largest Niagen Bioscience seller in Q2 2022 was BlackRock, an estimated $4.23M sold.
Based on aggregated 13F filings for Q2 2022.